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Abstract 
Background: Smoking cessation improves physical health but it has been 
suggested that in vulnerable individuals it may worsen mental health. This study 
aimed to identify the short- and longer-term effects of stopping smoking on 
depression and anxiety in the general population and those with a history of these 
disorders. 
Methods: Socio-demographic and smoking characteristics, mental and physical 
health were assessed using established measures in the ATTEMPT cohort, an 
international longitudinal study of smokers (N=3,645). Smokers who had stopped for 
at least 3 months or less than 3 months at 12 months follow-up were compared with 
current smokers (N=1,640). 
Results: At follow-up, 9.7% (95%CI 8.3-11.2) of smokers had stopped for less than 
three months and 7.5% (95%CI 6.3-8.9) for at least three months. Compared with 
current smokers, prevalence of depression prescriptions obtained in the last two 
weeks was lower for those who had stopped for less than (OR 0.37, 95%CI 0.14-
0.96) or at least three months (OR 0.25, 95%CI 0.06-0.94) after adjusting for 
baseline prescription levels and confounding variables. Adjusted prevalence of recent 
depression symptoms was also lower for ex-smokers who had stopped for less than 
(OR 0.34, 95%CI 0.15-0.78) or at least three months (OR 0.24, 95%CI 0.09-0.67) 
than among continuing smokers. There was no change in anxiety measures in the 
general population nor any increase in anxiety or depression symptoms in ex-
smokers with a past history of these conditions. 
Conclusions: Smoking cessation does not appear to be associated with an increase 
in anxiety or depression and may lead to reduced incidence of depression. 
 
Key words: smoking, smoking cessation, mental health, anxiety, depression, 
longitudinal 
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Introduction 
Smoking cessation improves physical health and reduces the risk of premature death 
(Taylor et al. 2002; Doll et al. 2004). However, its effect on mental health is uncertain 
(West & Jarvis, 2005). Cross-sectional studies consistently show a clear association 
between smoking and poor mental health, with current smokers having a higher 
prevalence of several psychiatric disorders including depression and anxiety than 
never- and ex-smokers (Glassman et al. 1990; Breslau et al. 1994; Breslau 1995; 
Breslau & Klein, 1999; Farrell et al. 2001; Degenhardt et al. 2001; Benjet et al. 2004; 
Grant et al. 2004; Wiesbeck et al. 2008). This may be due to several reasons. 
Smoking behaviour and poor mental health may share a common aetiology based on 
genetic vulnerability (Kendler et al. 1993), early childhood environment (Goodwin et 
al. 2004) and personality traits (Goodwin & Hamilton, 2002). In addition, smoking 
may worsen mental health and stopping may improve it, or people with worse mental 
health could be more likely to start smoking and find it more difficult to stop, e.g. 
because they self-medicate (Breslau et al. 1998). Indeed, longitudinal studies show 
both that psychiatric illnesses leads to later smoking uptake (Brown et al. 1996; 
Patton et al. 1998; Breslau et al. 1998; Breslau et al. 2004) and that starting to smoke 
increases the risk of subsequent psychiatric morbidity (Johnson et al. 2000; 
Klungsoyr et al. 2006; Steuber & Danner, 2006; Boden et al. 2010; Kang & Lee, 
2010), suggesting a reciprocal relationship. However, most research has focused on 
either the onset of mental illness following uptake of smoking or uptake of smoking 
following the onset of mental illness. Less is known about the effects of smoking 
cessation on mental health in general and depression and anxiety in particular. 
 
A large body of opinion postulates that smoking may, through the actions of nicotine, 
have beneficial effects on mental health, for example acting as an anxiolytic, and aid 
in self-medication to relieve perceived psychological or physiological symptoms 
(Morrell & Cohen, 2006; Morissette et al. 2007; Ziedonis et al. 2008). If that were the 
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case, one might expect mental health to deteriorate, particularly in vulnerable 
individuals who stop smoking. In agreement with this, some reports indicate 
increased incidence of depressive episodes in people with a history of major 
depressive disorder who have stopped smoking, linking these to cessation (Flanagan 
& Maany, 1982; Glassman et al. 1990; Glassman et al. 2001; Aubin 2009). Moreover, 
general population studies have shown that mood disturbances do not necessarily 
resolve following a month of abstinence from smoking (Gilbert et al. 1999; Gilbert et 
al. 2002) and that smokers with a history of depression or those who experience 
more negative affect during a quit attempt are more likely to relapse (Kassel et al. 
2003; Piasecki et al. 2003; Rohde et al. 2004). 
 
Yet, short to longer-term cessation has also been associated with a decrease in 
stress and anxiety and no worsening of depressed mood in the general population 
(West & Hajek, 1997; Hajek et al. 2010; Bolam et al. 2011) and with a faster recovery 
among those with a current diagnosis of depression or anxiety (Jamal et al. 2012). 
While there is evidence that acute negative affect may precipitate relapse (Shiffman 
& Waters, 2004), meta-analyses have failed to corroborate findings that a history of 
depression predicts smoking cessation outcomes (Hitsman et al. 2003; Covey et al. 
2006). In addition, randomised controlled trials of smoking cessation interventions 
show that smokers with mental illness can achieve abstinence rates comparable to 
those of general population samples (Banham & Gilbody, 2010). 
 
Given these contradictory findings, more research is needed into the association of 
mental health with smoking cessation to better understand causal relationships 
(Morrell & Cohen, 2006). However, much of what we know about the impact of 
smoking cessation on mental health comes from randomised controlled trials rather 
than naturalistic, observational studies, and cohort studies that can address the issue 
by comparing continuing smokers with those who stop are relatively rare (Ziedonis et 
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al. 2008). Most large-scale studies in this area tend to be cross-sectional and 
retrospective (Mykletun et al. 2008; McClave et al. 2009) and prospective studies 
have often parochial and small sample sizes (Covey et al. 1997; Glassman et al. 
2001; Gilbert et al. 2002) limiting the conclusions that can be drawn. 
 
Thus there is an expressed need for longitudinal data on this issue with regular follow 
up in a sample that is representative of the general population of smokers. This 
paper reports on the impact of smoking cessation on self-reported depression and 
anxiety using data from ATTEMPT, the largest longitudinal, multi-national general 
population study yet to be conducted on this topic. Specifically, we investigate the 
following questions: 
1.) What is the impact of short- (<3 months) and longer-term (≥3 months) smoking 
cessation on the prevalence of depression and anxiety in a general population 
sample? 
2.) What is the impact of short- and longer-term smoking cessation on the prevalence 
of depression and anxiety among smokers with a history of these conditions? 
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Methods 
Study population and design 
Participants were selected from the ATTEMPT cohort; a multinational prospective 
study examining physical and mental health outcomes in individuals as a function of 
their smoking status. Full details of the study methodology are provided elsewhere 
(West et al. 2006). Briefly, participants were recruited via Harris Interactive,Inc. which 
maintains a market research panel with several million panellists in over 125 
countries. These panel members are internet users who have registered voluntarily 
and have agreed to complete regular online surveys for research purposes in 
exchange for points that can be redeemed for merchandise. The current analysis 
reports on phase two of this study, set up in 2004 in the USA, Canada, the UK, 
France and Spain. Following email invitations sent to a random sample of panellists 
in these countries, those that smoked at least five cigarettes a day, intended to quit 
within the following three months and were aged between 35-65 years were included. 
A total of 3,645 respondents met eligibility criteria. At baseline participants completed 
a self-report questionnaire received via email, and detailed follow-up questionnaires 
were completed via email approximately every three months for up to 18 months. 
Only participants who provided complete and consistent responses at both the 
baseline and 12 months follow-up (N=1,640) were included in the current analysis 
(see Table 1 for sample characteristics). 
 
Measures 
Smoking history and standard smoking characteristics, socio-demographic 
characteristics including age, sex, marital and employment status, ethnicity and 
educational attainment were collected at baseline and follow-up surveys and 
standardised across countries.  
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At baseline, smokers were asked to indicate length of time of smoking and recent 
quit attempts were determined by asking: “During the past 3 months (90 days), have 
you made a serious attempt to stop smoking for good that lasted for at least a day 
(24h)?”. Smokers were also asked if any cessation medications were used to support 
their quit attempt. Motivation to stop smoking was measured using a 10-point Likert 
scale: “In the following 10-point scale, please select the number that best describes 
your current motivation to quit smoking cigarettes” (1=not at all motivated, 10=highly 
motivated). Nicotine dependence was measured using the Fagerstrom Test of 
Nicotine Dependence (Heatherton et al. 1991), which places smokers on a ten point 
scale based on six items: time to first cigarette (0=60+ min; 1=31-60 min; 2=6-30 
min; 3=within 5 min); daily cigarette consumption (0=≤10, 1=11-20, 2=21-30, 3=31+); 
smoking when ill; more frequent smoking shortly after awakening; difficulty refraining 
from smoking in no-smoking areas (for all: 0=no; 1=yes); and the cigarette smokers 
hate most to give up (1=first in the morning, 0=any other). 
 
Smoking status at 12 months follow-up was assessed by asking participants “Are you 
currently a smoker?” and “Have you smoked any cigarettes today?”. Those who 
answered ‘yes’ to either or both questions were classified as ‘current smokers’. 
Participants who answered ‘no’ to both questions were further asked “How many 
days has it been since you last smoked a cigarette?” and a free-text response was 
recorded. Those who claimed to have not had a cigarette within the last 3 months 
were asked “Just to confirm, in the last 3 months (90 days) have you smoked any 
cigarettes (even a puff)?” Participants who answered ‘no’ were classified as ‘ex-
smokers ≥3 months’. Participants whose response suggested they had stopped 
smoking within the last 3 months were asked to confirm they had not smoked either 
in the last 30 days, 7 days or today. Those who answered ‘no’ to any of these options 
were classified as ‘ex-smokers <3 months’. Inconsistent responders (N=40) were 
excluded. 
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Physical and mental health was assessed at both baseline and follow-up. 
Participants were asked to provide their height and weight in order to calculate their 
body-mass-index. Respondents also completed the EuroQol (EQ-5D), a widely used 
measure of health-related quality of life (Rabin & de Charro, 2001). Mental health 
was determined by yes/no responses to single item measures which have been 
found to have good congruence with structured clinical interviews (McChargue & 
Werth, 2007). Life-time mental health diagnoses were assessed by asking “Have you 
ever been told by a doctor or other health care professional that you had any of the 
following conditions? 1) Depression, 2) Anxiety”. Recent mental health status was 
determined by asking “During the past 3 months, have you had symptoms or been 
bothered by any of the following conditions? 1) Depression, 2) Anxiety”. Respondents 
also noted their medication prescriptions, being asked “During the past 2 weeks, did 
you take medications that require a prescription from your doctor for the following 
conditions? 1) Depression, 2) Anxiety”. For ease of analysis, measures of depression 
and anxiety were also combined into a single measures of ‘any’ mental health 
problem. 
 
Analysis 
Data were analysed using SPSS 20.0 (IBM, New York). In unadjusted analyses 
between and within group differences were assessed with Χ2 test, Wilcoxon signed-
rank test or ANOVAs for categorical and continuous variables, respectively. Adjusting 
for all other factors in the model, logistic regressions were carried out providing odds 
ratios (OR) with 95% confidence intervals (CIs) in order to evaluate which, if any, of 
the variables were independently associated with mental health outcomes. 
Generalised estimating equations were used to compute mean-value adjusted levels 
of mental health outcomes by smoking status. Statistical significance was set at the 
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standard level (p<0.05) and in post-hoc analyses, the Sidak correction was applied to 
control for multiple comparisons. 
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Results 
A total of 45% of participants (N=1,640) completed both baseline and follow-up 
online questionnaires. Those lost to follow-up differed on a number of socio-
economic and smoking but on only few physical and mental health characteristics. 
Those lost to follow-up were slightly more likely to report a life-time diagnosis of any 
mental health problem, in particular depression (X2=4.6,df=1,p=0.032), but no other 
differences were apparent. Life-time prevalence of depression and anxiety in the 
retained sample was 22.3% (95%CI 20.2-24.2) and 27.4% (95%CI 25.1-29.4), 
respectively. Overall, a third (37.5%, 95%CI 35.2%-39.8%) reported any life-time 
diagnosis (Table 1). 
 
(Table 1 about here) 
 
At 12 months, 7.5% (95%CI 6.3-8.9) of smokers had stopped for at least three 
months and 9.7% (95%CI 8.3-11.2) for less than three months. There were few 
differences in baseline variables according to smoking status at follow-up (Table 1). 
Those who were smokers at 12 month follow up had been more nicotine dependent 
(F=10.5,dfbetween=2,dfwithin=1610,p<0.001) and less likely to have previously made a 
quit attempt at baseline (X2=16.4,df=2,p<0.001) than recent ex-smokers. They also 
scored marginally lower on the EQ-5D than longer-term ex-smokers 
(F=3.4,dfbetween=2,dfwithin=1603,p=0.035). 
 
1.) Impact of short- and longer-term smoking cessation on depression and anxiety 
prevalence in the general population 
At follow-up, current smokers were more likely to have received a prescription in the 
last two weeks for ‘any’ mental health problem than longer-term (≥3 months) ex-
smokers (Table 2). More specifically, longer-term ex-smokers were less likely to 
report receiving a prescription for depression, but not anxiety, than current smokers 
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(OR 0.26, 95%CI 0.09-0.71,p=0.009). There were no differences between current 
and recent (<3 months) ex-smokers. These results were broadly mirrored when 
looking at ‘any’ mental health symptoms experienced in the last three months (Table 
2). Longer-term and recent ex-smokers were less likely to report symptoms of 
depression, but not anxiety, than current smokers (OR 0.31, 95%CI 0.14-
0.67,p=0.003 and OR 0.53, 95%CI 0.31-0.92,p=0.025, respectively). 
 
(Table 2 about here) 
 
These findings were further substantiated using logistic regression models to control 
for potential confounders. Smoking status at follow-up did not impact reported 
prescriptions for anxiety in the last two weeks or experiencing symptoms of anxiety in 
the last three months at 12 months follow-up (Table 3a). However, the prevalence of 
receiving a prescription for depression in the last two weeks at follow-up was 
significantly lower among recent (7.0%; OR 0.37, 95%CI 0.14-0.96,p=0.041) and 
longer-term ex-smokers (6.2%; OR 0.25, 95%CI 0.06-0.94,p=0.040) than among 
current smokers (11.4%, Figure 1a). Similarly, prevalence of reported symptoms of 
depression experienced within the last three months was significantly lower among 
recent (10.2%; OR 0.34, 95%CI 0.15-0.78,p=0.011) and longer-term ex-smokers 
(8.1%; OR 0.24, 95%CI 0.09-0.67,p=0.006) than among current smokers (16.5%) at 
12 months follow-up (Figure 1b). 
 
(Table 3 about here) 
 
As expected, baseline prescription levels and symptoms of depression or anxiety 
were the strongest predictors of a recent prescription and experiencing symptoms of 
depression or anxiety at 12 months-follow up (Table 3a). There were some country-
level differences, with participants from the US reporting highest levels of depression 
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prescriptions and symptoms. In addition, those who were married, employed and 
showed an increase in their health-related quality of life from baseline were less likely 
to report receiving a prescription for, or experiencing, depression symptoms at follow-
up. Conversely, those who were male, employed, less nicotine dependent and had 
improved health-related quality of life, and to a lesser degree those who were less 
motivated to quit and had made no recent quit attempt at baseline, were less likely to 
report receiving a prescription for, or experiencing, anxiety symptoms at follow-up 
(Table 3a).  
 
2.) Impact of short and longer term smoking cessation on depression and anxiety 
prevalence among those with a history of mental health problems 
As expected the prevalence of indicators of recent mental health problems, 
depression and anxiety symptoms experienced in the last three months and relevant 
prescriptions received in the last two weeks, was higher in this vulnerable population 
than in the general population (Figure 1). Ex-smokers of at least three months were 
less likely to report receiving prescriptions for, or experiencing, ‘any’ mental health 
problem than current smokers in unadjusted analysis (Table 2). This was the case for 
prescriptions for depression (OR 0.27, 95%CI 0.09-0.76,p=0.014) and experiencing 
symptoms of depression (OR 0.33, 95%CI 0.14-0.75,p=0.008) but not anxiety. Ex-
smokers of less than three months were also less likely to report experiencing 
depression symptoms in the last three months (OR 0.50, 95%CI 0.27-0.92,p=0.026) 
than those who continued smoking (Table 2). 
 
(Figure 1 about here) 
 
As Figure 1 shows, differences between current and ex-smokers with a history of 
mental health problems were largely attenuated in adjusted analysis with two 
exceptions: the prevalence of having received a prescription for ‘any’ mental health 
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problem in the last two weeks was significantly lower among longer-term ex-smokers 
(20.5%) than current smokers (35.6%; OR 0.24, 95%CI 0.07-0.77,p=0.016) and the 
prevalence of experiencing symptoms of depression in the last three months was 
significantly lower among recent ex-smokers (23.7%) than current smokers (36.6%; 
OR 0.36, 95%CI 0.14-0.92,p=0.033; Table 3b). Generally, odds ratios were 
comparable to those from the general population. 
 
As before, baseline prescription levels and symptoms of depression or anxiety were 
the strongest predictors of a recent prescription and experiencing symptoms of 
depression or anxiety at 12 months-follow up (Table 3b). The level of depression 
prescription and symptom was again higher in the US compared with other countries. 
In addition, as in the general population, those who were married, employed and 
showed an increase in their health score from baseline were less likely to report 
receiving a prescription for, or experiencing, depression symptoms at follow-up. 
Likewise, those who were male were less likely to report receiving a prescription for, 
or experiencing, anxiety symptoms at follow-up and those who were more motivated 
to quit and had made a recent quit attempt at baseline were also more likely to report 
receiving a prescription for anxiety in the last two weeks (Table 3b). 
 
(Figure 2 about here) 
 
In order to delineate the causal direction of the observed association of smoking 
cessation with mental health, sensitivity analyses were carried out. It was reasoned 
that the findings may be an artefact. Self-selection could account for the results as 
smokers who are more prone to become depressed upon cessation may be more 
likely to relapse and continue to smoke. In this scenario, there would be no change 
over time in the total prevalence of mental health problems in the cohort. The 
decrease in prevalence of mental health problems among ex-smokers - those who 
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are less vulnerable to psychiatric morbidities and are therefore able to stop - would 
be offset by an increase in the prevalence of mental health problems in the remaining 
pool of current smokers - those who are more vulnerable to psychiatric morbidities 
and find it difficult to stop (Figure 2A). Alternatively, if smoking cessation improved 
mental health, one would expect that with an increase in ex-smokers in the cohort, 
there should be an overall decrease in the prevalence of mental health problems as 
there would be no change among current smokers but a decline among ex-smokers 
(Figure 2A). 
 
Figures 2B and C show a pattern of no change or a decrease in the prevalence of 
reported mental health outcomes among current smokers and a pronounced 
decrease among ex-smokers, consistent with the latter but not former interpretation. 
There was a non-significant overall decrease in prescriptions from 15.5% to 14.9% in 
the total population, no change among current smokers and a decline among ex-
smokers resulting in significant differences between ex- and current smokers at 
follow-up (Χ2=4.2,df=1,p=0.04) but not at baseline (Figure 2B). There was also a 
significant decrease in prescriptions among those with mental health problems from 
41.5% to 34.3% (Wilcoxon Z=3.69,p<0.001). Whilst this was the case for both 
continuing smokers (Wilcoxon Z=2.04,p=0.041) and ex-smokers (Wilcoxon 
Z=3.13,p=0.002), possibly reflecting regression towards the mean, this decline was 
steeper among ex-smokers who were less likely than smokers to report receiving 
prescriptions for ‘any’ mental health problems in the last two weeks at follow-up 
(Χ2=4.7,df=1,p=0.03) but not baseline. 
 
The pattern was broadly similar for mental health problems experienced in the last 
three months, reducing significantly from 28.7% to 26.1% in the overall sample 
(Wilcoxon Z=2.45,p=0.014). This decline was only present among those who had 
stopped smoking (Wilcoxon Z=3.37,p<0.001; Figure 2C). Among those with a history 
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of mental health problems, there was also an overall significant decline from 76.6% 
to 55.8% (Wilcoxon Z=2.45,p=0.014). As before this may be a result of regression 
towards the mean, being present among both current (Wilcoxon Z=7.09,p<0.001) 
and ex-smokers (Wilcoxon Z=2.54,p=0.019). However, the decline was again steeper 
among ex-smokers since there were no differences between groups at baseline but 
there were at follow up (Χ2=7.4,df=1,p=0.007). 
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Discussion 
Depression and anxiety as assessed in this cohort of smokers was common, with 
one in three reporting a life-time diagnosis of either condition and one in four 
experiencing recent symptoms. These estimates are broadly similar to previous 
studies confirming much higher incidence and prevalence rates among smokers than 
non-smokers (Perez-Stable et al. 1990; Breslau et al. 1991; Grant et al. 2004; 
McClave et al. 2009; Lawrence et al. 2009). In agreement with previous research 
(West & Hajek, 1997; McClave et al. 2009; Bolam et al. 2011), this study provides 
evidence that smoking cessation in the general population does not result in an 
increase in mental health problems and may be associated with a decrease in 
depression. Similar to a cross-sectional analysis, these effects appeared largely 
independent of the length of abstinence (Mykletun et al. 2008). 
 
In contrast to some (Glassman et al. 1990; Covey et al. 1997; Glassman et al. 2001) 
but not other work (Haustein et al. 2002; Jamal et al. 2012), there was no evidence of 
an exacerbation of symptoms following smoking cessation among those with a 
history of mental health problems. This divergence may be due to a number of 
factors. This analysis provides a larger sample than most previous studies and 
includes participants from several countries. In addition, it is possible that the 
association of smoking cessation and deterioration in mental health may be a 
function of the severity of past mental health problems which was not assessed in the 
current study. However, even in studies reporting an increased risk of depressive 
episodes following cessation, rates were very low (Morrell & Cohen, 2006; Ziedonis 
et al. 2008) suggesting that this may be an issue for only a small proportion of 
smokers with a history of mental health problems. 
 
In line with previous studies in general or patient populations, being married 
(Weissman et al. 1996; Frech & Williams, 2007) or in employment (Murphy & 
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Athanasou, 1999) was independently associated with lower rates of depression and 
men were less likely than women to display anxiety symptoms (West & Hajek, 1997; 
Lewinsohn et al. 1998; Pigott 1999; McClave et al. 2009). In addition, as shown 
previously, greater nicotine dependence was associated with anxiety (Goodwin et al. 
2011), and improvement in general health was associated with better mental health 
(Wise & Taylor, 1990; Sherbourne et al. 1996; Patten 2001; Ruo et al. 2003; Evans 
et al. 2005; Beard et al. 2007; Janney et al. 2008; Carek et al. 2011). 
 
This study has some limitations. As data were collected online, smoking status and 
mental health were assessed by self-report rather than clinical assessment. 
However, self-report in surveys has been shown to be a valid indicator of both 
current smoking (Patrick et al. 1994) and mental health status (McChargue & Werth, 
2007). While the use of prescription as an indicator is problematic as prescription 
policies and practices vary between countries of included participants, several 
measures of mental health were used to increase reliability, yielding similar results, 
and country was included as a confounder in analysis. Moreover, prevalence 
estimates and observed associations with a range of socio-demographic variables 
replicate previous findings of studies using standard measures of mental health, 
further corroborating this approach. Whilst numerous covariates were included in the 
analysis, it is possible that inclusion of other uncontrolled variables, for instance 
common vulnerability factors for both mental health and smoking such as impulsivity 
or neuroticism (Bienvenu et al. 2001; Hooten et al. 2005), could have altered results. 
In addition, self-selection cannot be excluded as an explanation for the findings. 
However, this problem could only be overcome using a randomised controlled design 
which would be unethical and sensitivity analysis showed that it is unlikely that self-
selection alone can account for the observed associations. Lastly, given that this 
sample comprises internet users, aged 35-64, who volunteered to participate this 
may affect the generalizability of findings. However, previous analysis has shown that 
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characteristics of this sample show high congruence with characteristics of 
equivalent national probability-based samples of the respective countries of 
participants (West et al. 2006). This study also had strengths. The longitudinal design 
allowed for an analysis of temporal associations in a large sample drawn from the 
general population across different countries, controlling for a multitude of 
confounders which strengthens the generalizability of findings. 
 
Our findings add substantially to a growing literature suggesting that smoking 
cessation may not only be beneficial for physical but also mental health in the 
general population and that it does not exacerbate symptoms of depression or 
anxiety among those with a history of these conditions. These outcomes may be 
explained by the adverse effects that chronic smoking has on neurophysiological 
substrates, being linked to changes in monoamine oxidase activity (Fowler et al. 
1996) and levels of brain-derived neurotrophic factor (Kim et al. 2007) which have 
been implicated in the aetiology of psychopathology (Pintar & Breakefield, 1982; Sen 
et al. 2008). It has also been postulated that the frequent unpleasant withdrawal 
symptoms experienced by smokers may lead to the development and maintenance 
of mental health problems (Parrott 2006). In this context it is important to reiterate 
that smokers with mental health problems are just as motivated to stop smoking as 
those in the general population and that smoking cessation interventions are equally 
effective in this group of smokers (Ziedonis et al. 2008; Campion et al. 2008). Thus 
smokers with and without current psychiatric comorbidities should be encouraged to 
stop smoking given the great benefits that smoking cessation provides. 
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Tables 
Table 1: Baseline sample characteristics by follow-up status and smoking status at follow-up 
 
 
Total 
Sample 
(N=3645) 
 
Lost to follow-
up (N=2005) 
Followed-up 
(N=1640) 
 Smoking status at 12 months follow-up 
Ex-smoker ≥ 
3 months 
(N=123) 
Ex-smoker < 
3 months 
(N=159) 
Current 
smoker 
(N=1358) 
Sociodemographic characteristics         
Mean (SD) Age 45.8 (7.3)  45.4 (7.1) 46.3 (7.5)***  47.1 (7.9) 46.7 (7.8) 46.2 (7.4) 
% (N) Women 48.0 (1750)  50.3 (1009) 45.2 (741)**  45.5 (56) 40.9 (65) 45.7 (620) 
% (N) Married 47.4 (1729)  44.4 (890) 51.2 (839)***  50.4 (62) 47.8 (76) 51.6 (701) 
% (N) Employed# 72.2 (2632)  71.4 (1427) 73.6 (1205)  77.2 (95) 76.6 (121) 72.9 (989) 
% (N) White 93.3 (3400)  93.7 (1879) 92.7 (1521)  95.1 (117) 95.0 (151) 92.3 (1253) 
% (N) Education^ 
            No high school 
            Some high school 
            High school 
            Some college 
            College 
            Graduate school 
 
4.5 (163) 
5.9 (215) 
31.6 (1150) 
27.8 (1014) 
8.9 (324) 
21.2 (771) 
 
 
5.5 (109) 
6.5 (129) 
33.6 (672) 
25.7 (514) 
8.8 (176) 
20.0 (399) 
 
3.3 (54)* 
5.3 (86) 
29.2 (478)* 
30.5 (500)** 
9.0 (148) 
22.7 (372) 
  
4.9 (6) 
1.6 (2) 
30.1 (37) 
30.1 (37) 
11.4 (14) 
22.0 (27) 
 
4.4 (7) 
5.0 (8) 
28.3 (45) 
28.9 (46) 
10.7 (17) 
22.6 (36) 
 
3.0 (41) 
5.6 (76) 
29.2 (396) 
30.8 (417) 
8.6 (117) 
22.8 (309) 
% (N) Country 
            US 
            Canada 
            UK 
            France 
            Spain 
 
19.9 (725) 
2.8 (102) 
33.0 (1203) 
33.2 (1209) 
11.1 (406) 
 
 
14.4 (288) 
2.2 (45) 
38.3 (767) 
35.0 (702) 
10.1 (203) 
 
26.6 (437)*** 
3.5 (57) 
26.6 (436)*** 
30.9 (507)* 
12.4 (203) 
  
22.8 (28) 
4.1 (5) 
38.2 (47) 
22.8 (28) 
12.2 (15) 
 
21.4 (34) 
2.5 (4) 
30.8 (49) 
34.0 (54) 
11.3 (18) 
 
27.6 (375) 
3.5 (48) 
25.0 (340) 
31.3 (425) 
12.5 (170) 
Cigarette smoking characteristics         
Mean (SD) Years of smoking 28.5 (9.4)  28.2 (9.3) 29.0 (9.4)**  29.8 (9.4) 29.8 (9.0) 28.8 (9.5) 
Mean (SD) Nicotine Dependence score~ 4.7 (2.4)  4.7 (2.4) 4.7 (2.4)  4.4 (2.6)a,b 3.9 (2.5)a 4.8 (2.4)b 
Mean (SD) Motivation to quit 6.8 (1.9)  6.8 (1.9) 6.9 (1.8)  7.0 (1.7) 7.1 (1.8) 6.9 (1.9) 
% (N) Quit attempt in past 3 months‡ 29.1 (983)  30.9 (572) 27.0 (411)*  20.5 (23)a 40.1 (61)b 26.0 (327)a 
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Total 
Sample 
(N=3645) 
 
Lost to follow-
up (N=2005) 
Followed-up 
(N=1640) 
 Smoking status at 12 months follow-up 
Ex-smoker ≥ 
3 months 
(N=123) 
Ex-smoker < 
3 months 
(N=159) 
Current 
smoker 
(N=1358) 
% (N) Use of cessation medication in past 
3 months 
25.7 (937)  27.9 (559) 23.0 (378)** 
 
15.4 (19) 25.2 (40) 23.5 (319) 
Physical / mental health characteristics         
Mean (SD) Body Mass Index 26.8 (5.5)  26.5 (5.5) 27.1 (5.4)***  27.8 (4.9) 27.9 (5.6) 27.0 (5.5) 
Mean (SD) EQ-5D Score” 0.76 (0.26)  0.75 (0.27) 0.76 (0.26)  0.82 (0.22)a 0.78 (0.23)a,b 0.76 (0.27)b 
% (N) Life time diagnosis         
 Any 39.5 (1439)  41.1 (824) 37.5 (615)*  35.8 (44) 39.6 (63) 37.4 (508) 
 Depression† 24.0 (870)  25.4 (506) 22.3 (364)*  16.3 (20) 20.3 (32) 23.1 (312) 
 Anxiety† 28.0 (1016)  28.5 (569) 27.4 (447)  25.2 (31) 28.5 (45) 27.5 (371) 
% (N) Prescription in past 2 weeks         
 Any 15.4 (561)  15.3 (306) 15.5 (255)  9.8 (12) 15.7 (25) 16.1 (218) 
 Depression 10.1 (369)  10.5 (210) 9.7 (159)  4.9 (6) 9.4 (15) 10.2 (138) 
 Anxiety 9.4 (341)  9.0 (180) 9.8 (161)  5.7 (7) 8.8 (159) 10.3 (140) 
% (N) Symptom in past 3 months         
 Any 29.5 (1075)  30.1 (604) 28.7 (471)  26.8 (33) 30.2 (48) 28.7 (390) 
 Depression’ 16.0 (581)  16.5 (330) 15.3 (251)  10.6 (13) 13.2 (21) 16.0 (217) 
 Anxiety’ 21.5 (781)  21.8 (437) 21.0 (344)  18.7 (23) 24.5 (39) 20.8 (282) 
~
80 missing;
 #
9 missing; 
^
8 missing; 
‡
267 missing; “84 missing; 
†
18 missing; 
‘
6 missing; *p<0.05, **p<0.01, ***p<0.001; Different letters in superscript 
indicate significant differences (p<0.05); SD: standard deviation 
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Table 2: Mental health outcomes at follow-up by smoking status and mental health history 
 
 
Total 
Follow-up 
 
Current 
smoker (1) 
Ex-smoker < 
3 months (2) 
Ex-smoker ≥ 
3 months (3) 
2 vs 1 3 vs 1 
General population N=1640  N=1358 N=159 N=123 Odds ratio (95%CI) 
% (N) Prescription in past 2 weeks        
 Any 14.9 (245)  15.8 (214) 13.8 (22) 7.3 (9) 0.86 (0.54-1.38) 0.42 (0.21-0.85)* 
 Depression 10.4 (171)  11.5 (156) 6.9 (11) 3.3 (4) 0.57 (0.30-1.08) 0.26 (0.09-0.71)** 
 Anxiety 9.0 (147)  9.2 (125) 9.4 (15) 5.7 (7) 1.03 (0.59-1.80) 0.60 (0.27-1.31) 
% (N) Symptom in last 3 months        
 Any 26.1 (428)  27.4 (372) 22.0 (35) 17.1 (21) 0.75 (0.51-1.11) 0.55 (0.34-0.89)* 
 Depressiona 15.0 (245)  16.5 (223) 9.5 (15) 5.7 (7) 0.53 (0.31-0.92)* 0.31 (0.14-0.67)** 
 Anxietya 19.1 (313)  19.7 (267) 17.1 (27) 15.6 (19) 0.84 (0.54-1.30) 0.75 (0.45-1.25) 
Population with mental health history^ N=615  N=508 N=63 N=44   
% (N) Prescription in past 2 weeks        
 Any 34.3 (211)  36.2 (184) 31.7 (20) 15.9 (7) 0.82 (0.47-1.44) 0.33 (0.15-0.76)** 
 Depression 24.9 (153)  27.2 (138) 17.5 (11) 9.1 (4) 0.57 (0.29-1.12) 0.27 (0.09-0.76)* 
 Anxiety 21.1 (130)  22.0 (112) 20.6 (13) 11.4 (5) 0.92 (0.48-1.75) 0.45 (0.18-1.18) 
% (N) Symptom in past 3 months        
 Any 55.8 (343)  58.3 (296) 47.6 (30) 38.6 (17) 0.65 (0.39-1.10) 0.45 (0.24-0.85)* 
 Depression 33.7 (207)  36.6 (186) 22.2 (14) 15.9 (7) 0.50 (0.27-0.92)* 0.33 (0.14-0.75)** 
 Anxiety 42.1 (259)  43.5 (221) 36.5 (23) 34.1 (15) 0.75 (0.43-1.28) 0.67 (0.35-1.28) 
a
5 missing; *p<0.05; **p<0.01; ^With history of depression and/or anxiety; CI: confidence interval 
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Table 3: Association of baseline characteristics and smoking status at follow-up with mental health outcomes at follow-up  
a) Total Sample 
Prescription for condition in past 2 weeks (OR, 95% CI) Symptom in past 3 months (OR, 95% CI) 
Any 
(N=1423) 
Depression 
(N=1423) 
Anxiety 
(N=1423) 
Any 
(N=1423) 
Depression 
(N=1417) 
Anxiety 
(N=1417) 
Age 1.03 (1.00-1.05)* 1.01 (0.99-1.04) 1.02 (0.98-1.05) 1.02 (1.00-1.04) 1.01 (0.99-1.04) 1.00 (0.98-1.02) 
Gender1 1.44 (0.98-2.12) 1.03 (0.66-1.61) 2.34 (1.42-3.86)** 1.72 (1.28-2.33)*** 1.05 (0.71-1.57) 1.93 (1.39-2.68)*** 
Marriage Status2 0.75 (0.51-1.09) 0.53 (0.34-0.82)** 1.06 (0.66-1.72) 1.02 (0.76-1.37) 0.54 (0.37-0.80)** 1.04 (0.76-1.43) 
Employment Status3 
0.51 (0.34-
0.75)*** 
0.47 (0.30-0.73)** 0.49 (0.30-0.82)** 0.64 (0.46-0.88)** 0.44 (0.29-0.66)*** 0.65 (0.46-0.92)* 
Ethnicity4 0.53 (0.27-1.03) 0.53 (0.25-1.13) 0.46 (0.20-1.06) 0.67 (0.39-1.16) 0.81 (0.40-1.66) 0.73 (0.40-1.33) 
Education 
  No high school 
  Some high school 
  High school 
  Some college 
  College 
  Graduate school 
 
1 
0.77 (0.22-2.74) 
1.04 (0.38-2.87) 
1.07 (0.38-3.02) 
1.48 (0.48-4.63) 
0.99 (0.35-2.83) 
 
1 
2.52 (0.50-12.6) 
2.75 (0.70-10.8) 
2.06 (0.50-8.41) 
3.04 (0.67-13.8) 
1.86 (0.45-7.76) 
 
1 
0.10 (0.02-0.55)** 
0.42 (0.13-1.33) 
0.56 (0.17-1.80) 
0.44 (0.12-1.67) 
0.36 (0.11-1.17) 
 
1 
0.54 (0.19-1.54) 
1.00 (0.43-2.36) 
0.85 (0.36-2.03) 
1.19 (0.46-3.05) 
0.86 (0.36-2.07) 
 
1 
1.41 (0.32-6.20) 
2.14 (0.62-7.35) 
1.60 (0.45-5.66) 
2.40 (0.62-9.25) 
1.54 (0.43-5.51) 
 
1 
0.30 (0.10-0.91)* 
0.75 (0.32-1.79) 
0.74 (0.31-1.79) 
0.83 (0.32-2.19) 
0.72 (0.30-1.74) 
Country 
  US 
  Canada 
  UK 
  France 
  Spain 
 
1 
0.63 (0.23-1.76) 
0.84 (0.49-1.45) 
0.73 (0.44-1.21) 
0.85 (0.41-1.77) 
 
1 
0.79 (0.24-2.57) 
0.67 (0.37-1.22) 
0.47 (0.26-0.85)* 
0.38 (0.14-0.99)* 
 
1 
0.50 (0.13-1.87) 
0.69 (0.31-1.51) 
1.15 (0.60-2.21) 
1.63 (0.70-3.80) 
 
1 
0.90 (0.41-2.00) 
0.95 (0.62-1.46) 
1.10 (0.73-1.64) 
0.82 (0.47-1.44) 
 
1 
0.83 (0.30-2.27) 
0.65 (0.38-1.10) 
0.42 (0.24-0.72)** 
0.38 (0.17-0.86)* 
 
1 
1.02 (0.41-2.55) 
1.01 (0.62-1.65) 
1.55 (1.00-2.42) 
1.15 (0.63-2.10) 
Nicotine Dependence score 1.08 (1.00-1.18) 1.04 (0.95-1.15) 1.14 (1.03-1.27)* 1.08 (1.01-1.15)* 1.01 (0.93-1.10) 1.10 (1.03-1.18)** 
Motivation to quit 1.07 (0.97-1.19) 0.99 (0.88-1.11) 1.21 (1.06-1.38)** 1.04 (0.96-1.12) 0.94 (0.85-1.05) 1.06 (0.98-1.16) 
Quit attempt in past 3 
months 
1.27 (0.82-1.96) 1.05 (0.63-1.76) 2.02 (1.19-3.42)** 1.43 (1.03-2.00)* 1.33 (0.84-2.09) 1.26 (0.88-1.81) 
Cessation medication used 
in past 3 months5 
1.06 (0.67-1.69) 0.89 (0.51-1.55) 1.05 (0.59-1.89) 1.35 (0.94-1.93) 1.15 (0.71-1.85) 1.30 (0.87-1.89) 
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a) Total Sample 
Prescription for condition in past 2 weeks (OR, 95% CI) Symptom in past 3 months (OR, 95% CI) 
Any 
(N=1423) 
Depression 
(N=1423) 
Anxiety 
(N=1423) 
Any 
(N=1423) 
Depression 
(N=1417) 
Anxiety 
(N=1417) 
Change in Body Mass 
Index6 
1.03 (0.95-1.12) 0.99 (0.91-1.09) 1.02 (0.92-1.13) 1.04 (0.97-1.12) 1.06 (0.98-1.15) 0.99 (0.92-1.07) 
Change in Health Score6 0.36 (0.16-0.80)* 0.24 (0.09-0.60)** 0.47 (0.17-1.26) 0.20 (0.10-0.40)*** 0.16 (0.07-0.36)*** 0.36 (0.18-0.74)** 
Baseline equivalent to 
dependent variable 
26.8 (17.9-
40.1)*** 
35.9 (21.8-59.2)*** 46.1 (27.0-78.8)*** 14.1 (10.3-19.1)*** 33.1 (21.6-50.8)*** 13.2 (9.5-18.5)*** 
Smoking status 
  Smoker 
  Ex-smoker (< 3 months) 
  Ex-smoker (≥ 3 months) 
 
1 
0.74 (0.37-1.46) 
0.28 (0.10-0.78)* 
 
1 
0.37 (0.14-0.96)* 
0.25 (0.06-0.94)* 
 
1 
1.38 (0.63-3.04) 
0.57 (0.18-1.76) 
 
1 
0.52 (0.31-0.88)* 
0.38 (0.20-0.73)** 
 
1 
0.34 (0.15-0.78)* 
0.24 (0.09-0.67)** 
 
1 
0.67 (0.38-1.17) 
0.67 (0.34-1.31) 
 
b.) Sample with mental 
health history^ 
Prescription for condition in past 2 weeks (OR, 95% CI) Symptom in past 3 months (OR, 95% CI) 
Any 
(N=536) 
Depression 
(N=536) 
Anxiety 
(N=536) 
Any 
(N=536) 
Depression 
(N=536) 
Anxiety 
(N=536) 
Age 1.05 (1.02-1.08)** 1.03 (1.00-1.07) 1.02 (0.98-1.06) 1.04 (1.01-1.07) 1.03 (0.99-1.06) 1.00 (0.97-1.03) 
Gender1 1.16 (0.73-1.84) 0.82 (0.49-1.38) 1.88 (1.07-3.32)* 1.48 (1.00-2.18) 0.96 (0.59-1.57) 1.50 (1.01-2.23)* 
Marriage Status2 0.72 (0.46-1.12) 0.47 (0.28-0.79)** 1.04 (0.60-1.78) 0.92 (0.63-1.34) 0.42 (0.26-0.69)** 0.93 (0.63-1.36) 
Employment Status3 0.54 (0.34-0.87)* 0.47 (0.28-0.79)** 0.60 (0.33-1.07) 0.64 (0.42-0.98) 0.37 (0.22-0.62)*** 0.75 (0.49-1.14) 
Ethnicity4 0.54 (0.23-1.27) 0.73 (0.29-1.86) 0.42 (0.16-1.12) 0.64 (0.30-1.38) 0.98 (0.40-2.42) 0.76 (0.36-1.58) 
Education 
  No high school 
  Some high school 
  High school 
  Some college 
  College 
  Graduate school 
 
1 
0.64 (0.15-2.79) 
1.48 (0.46-4.72) 
1.36 (0.42-4.48) 
2.45 (0.65-9.17) 
1.07 (0.32-3.57) 
 
1 
1.16 (0.19-6.98) 
2.71 (0.64-11.4) 
1.96 (0.45-8.57) 
3.44 (0.69-17.2) 
1.44 (0.32-6.53) 
 
1 
0.16 (0.03-1.06) 
0.65 (0.17-2.55) 
0.72 (0.18-2.90) 
0.58 (0.12-2.80) 
0.37 (0.09-1.54) 
 
1 
0.31 (0.08-1.18) 
0.85 (0.28-2.57) 
0.74 (0.24-2.27) 
0.80 (0.24-2.71) 
0.72 (0.23-2.24) 
 
1 
0.77 (0.14-4.07) 
1.77 (0.47-6.69) 
1.43 (0.37-5.55) 
1.50 (0.33-6.83) 
1.13 (0.29-4.50) 
 
1 
0.23 (0.06-0.88)* 
0.72 (0.24-2.10) 
0.67 (0.22-2.00) 
0.63 (0.19-2.10) 
0.66 (0.22-2.00) 
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b.) Sample with mental 
health history^ 
Prescription for condition in past 2 weeks (OR, 95% CI) Symptom in past 3 months (OR, 95% CI) 
Any 
(N=536) 
Depression 
(N=536) 
Anxiety 
(N=536) 
Any 
(N=536) 
Depression 
(N=536) 
Anxiety 
(N=536) 
Country 
  US 
  Canada 
  UK 
  France 
  Spain 
 
1 
0.42 (0.11-1.57) 
0.71 (0.37-1.38) 
0.46 (0.25-0.84)* 
0.61 (0.25-1.46) 
 
1 
0.92 (0.19-4.37) 
0.55 (0.27-1.11) 
0.33 (0.17-0.65)** 
0.34 (0.12-0.99)* 
 
1 
0.17 (0.03-0.88)* 
0.64 (0.27-1.55) 
0.74 (0.35-1.53) 
1.17 (0.44-3.15) 
 
1 
0.46 (0.14-1.48) 
0.69 (0.39-1.22) 
0.62 (0.37-1.05) 
0.53 (0.26-1.10) 
 
1 
0.38 (0.09-1.63) 
0.45 (0.23-0.87)* 
0.26 (0.13-0.49)*** 
0.29 (0.11-0.75)* 
 
1 
0.71 (0.20-2.49) 
0.70 (0.39-1.27) 
0.92 (0.54-1.57) 
0.83 (0.40-1.73) 
Nicotine Dependence score 1.06 (0.96-1.17) 1.01 (0.91-1.13) 1.11 (0.99-1.25) 1.07 (0.99-1.16) 1.00 (0.90-1.11) 1.07 (0.98-1.16) 
Motivation to quit 1.07 (0.94-1.21) 1.02 (0.89-1.17) 1.19 (1.02-1.38)* 1.02 (0.92-1.13) 0.97 (0.85-1.10) 1.04 (0.93-1.15) 
Quit attempt in past 3 
months 
1.04 (0.61-1.77) 0.78 (0.42-1.45) 2.03 (1.10-3.74)* 1.56 (1.00-2.43) 1.12 (0.62-2.00) 1.31 (0.85-2.04) 
Cessation medication used 
in past 3 months5 
0.93 (0.53-1.64) 0.82 (0.43-1.57) 0.84 (0.43-1.65) 1.21 (0.75-1.93) 0.95 (0.52-1.73) 1.26 (0.79-2.03) 
Change in Body Mass 
Index6 
1.00 (0.90-1.10) 0.95 (0.85-1.06) 1.01 (0.90-1.13) 1.05 (0.96-1.15) 1.05 (0.94-1.17) 1.00 (0.91-1.09) 
Change in Health Score6 0.56 (0.23-1.36) 0.36 (0.13-1.00)* 0.64 (0.23-1.83) 0.39 (0.18-0.85) 0.28 (0.11-0.74)* 0.50 (0.23-1.09) 
Baseline equivalent to 
dependent variable 
11.5 (7.13-18.5)* 13.6 (7.92-23.4)*** 23.9 (13.0-44.0)*** 3.94 (2.47-6.27) 12.6 (7.63-21.0)*** 5.24 (3.41-8.06)* 
Smoking status 
  Smoker 
  Ex-smoker (< 3 months) 
  Ex-smoker (≥ 3 months) 
 
1 
0.76 (0.35-1.65) 
0.24 (0.07-0.77)* 
 
1 
0.40 (0.15-1.09) 
0.26 (0.06-1.05) 
 
1 
1.28 (0.52-3.18) 
0.48 (0.13-1.80) 
 
1 
0.53 (0.28-0.98) 
0.39 (0.18-0.85) 
 
1 
0.36 (0.14-0.92)* 
0.33 (0.11-1.02) 
 
1 
0.66 (0.34-1.25) 
0.65 (0.29-1.43) 
1
Referent: Men; 
2
Referent: Not Married; 
3
Referent: Unemployed; 
4
Referent: Non-white; 
5
At follow-up; 
6
Positive score indicates increase from baseline; *p<0.05, 
**p<0.01, ***p<0.001; ^With history of depression and/or anxiety; CI: confidence interval 
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Figures 
Figure 1: Adjusted prevalence# of recent (A) medication prescription and (B) mental health symptoms by smoking status at 12 months follow-up in 
total sample and those with history of mental health illness^ 
#Estimated marginal means with confounders set at average values (error bars show 95% confidence intervals); ^With history of depression 
and/or anxiety; *p<0.05, **p<0.01 
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Figure 2: Changes in indices of mental health by smoking status and history of 
mental health problems; (A) Postulated change scenario as function of selection; (B) 
Change in medication prescription prevalence; (C) Change in symptom prevalence 
*p<0.05, **p<0.01, ***p<0.001; Error bars show 95% confidence intervals 
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